Novo Nordisk Q3 and other earnings/macro
Novo beat on sales but missed on EPS and operating profit, while Goldman raised its European EPS growth forecasts.
What we know
An account on X lists Novo's sales of DKK 79.2B against an estimate of 73.8B, with EPS and operating profit missing. Wegovy pill prescriptions hit 3.6M in Q3. Another account on X says Goldman raised its 2026 STOXX 600 EPS growth forecast to 18%.
How the story developed
Novo beat on sales but missed on EPS and operating profit, while Goldman raised its European EPS growth forecasts.
NEAR governance voted to cut max issuance to 1.6%, Goldman raised its European gas outlook on LNG-disruption risk, and Robinhood's prediction markets business reached about $500M ARR.
By the Global Eye 24 desk, with AI assistance. Updated as the story develops. Spot an error? Write to corrections@globaleye24.com.